Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pseudomyxoma Peritonei 1Ovarian Neoplasms 1Neoplasm Metastasis 1Leydig Cell Tumor 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Pharmacogenomic Testing × Gynecologic × Clear all
NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT01652794 2015-08-04

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Case Comprehensive Cancer Center

Phase 1 Completed
12 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Leydig Cell Tumor, Pseudomyxoma Peritonei, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡